Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor which has been implicated in numerous solid and hematologic cancers. ALK mutations are reported in about 5-7% of neuroblastoma cases but the ALK-positive percentage increases significantly in the relapsed patient population. Crizotinib,...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Siaw, Joachim T., Wan, Haiying, Pfeifer, Kathrin, Rivera, Victor M., Guan, Jikui, Palmer, Ruth H., Hallberg, Bengt
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5045374/
https://ncbi.nlm.nih.gov/pubmed/27049722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8508
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы